Physician profile
Shannon M Haggerty
NPI 1730390295
$2,705.67
in general payments reported to CMS, 2019-2025
26 companies · $254 in 2025
The $254 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $188 · 2021: $154 · 2022: $486 · 2023: $618 · 2024: $297 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $727.50 | 2019-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novo Nordisk INC | $279.01 | 2019-2020 | |
| Abbott Laboratories | $233.05 | 2019-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Lilly USA, LLC | $189.18 | 2019-2023 | Mounjaro |
| Boston Scientific Corporation | $175.32 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Astrazeneca Pharmaceuticals LP | $147.02 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $141.51 | 2022-2024 | Gvoke Hypopen |
| Beta Bionics, INC. | $139.12 | 2023 | Ilet Bionic Pancreas |
| Medtronic Minimed, INC. | $102.08 | 2019 | |
| Sanofi-Aventis U.S. LLC | $92.80 | 2019-2022 | |
| Insulet Corporation | $54.79 | 2022 | |
| Novartis Pharmaceuticals Corporation | $48.20 | 2025 | |
| Mannkind Corporation | $47.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $36.23 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $32.46 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.03 | 2019-2023 | Synjardy, Jardiance |
| Radius Health, INC. | $31.31 | 2019-2020 | |
| Amgen INC. | $26.02 | 2019-2020 | |
| Embecta Corp. | $25.60 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Lifescan, INC. | $24.53 | 2019 | |
| Merck Sharp & Dohme LLC | $24.21 | 2019-2020 | |
| Corcept Therapeutics | $23.13 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.84 | 2019 | |
| Tandem Diabetes Care, INC. | $20.40 | 2020 | |
| Abbvie INC. | $17.61 | 2019 | |
| Vivus LLC | $14.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Haggerty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.